The Next-Gen in Endoscopic Ultrasound-Guided Biopsy
Introducing Precision-GI™
The NextGen in Advanced Endoscopic Ultrasound-Guided Biopsy
Click here to see Precision-GI™ in action and discover how it can optimize EUS-guided biopsy tissue acquisition of pancreatic masses.
Our
Mission
To optimize Endoscopic Ultrasound-Guided Biopsy for high-quality tissue acquisition, supporting accurate pancreatic cancer diagnosis and timely, personalized patient therapy.
Our Achievements
Commercial and Reimbursement Milestones
FDA Breakthrough Device Designated
CMS Pass-Through Code Reimbursement
Commercially Launched in the United States
Regulatory Milestones
FDA 510(k) Cleared
ISO 13485 Certified
Discover How Precision-GI™
is Improving the Standard of Care
Unlike current Ultrasound Fine Needle Biopsy Needles (EUS-FNB) which are operated manually, Precision GI™ features a unique motorized rotational cutting mechanism, allowing consistent high quality tissue acquisition.
At Limaca Medical, we aim to improve the endoscopic biopsy experience for both interventional gastroenterologists and the patient, with:
Consistent high-quality tissue samples
Large core fragments with preserved architecture and reduced contamination.
Fewer passes. Less variability
Precision-GI™ controlled motorized tissue acquisition contributes to the reduction in the number of passes and actuations, designed to reduce operator-dependent procedural variability.
Precise sampling
Controlled sampling through high-speed rotational tissue cutting mechanism that eliminates repetitive axial manual needle stabbing.
Shorter time to treatment
Critical in aggressive pancreatic cancers, aimed to reduce redo cases and enabling timely and personalized treatment.
Enabling definitive diagnosis
Tissue adequacy for histopathological and molecular profiling testing, supporting confident clinical decisions in cancer therapy.
Operational efficiency
Requiring no changes to room setup, procedural workflow, or capital equipment. Operates within your existing endoscopic suite.
Reference: Robles-Medranda, C., et al. (2025). Evaluation of a novel motorized EUS-guided fine-needle biopsy device and pathology quality parameters comparison to standard fine-needle biopsy: A prospective pilot study. Gastrointestinal Endoscopy, 101(5), S592–S593.
How Superior Tissue Acquisition Transforms Patient Care
For busy cancer centers and patients anxiously waiting for a possible diagnosis of GI cancer, time is of the essence.
The quality of a single biopsy sample can shape a patient’s entire pathway.
Given the lack of procedural standardization with conventional manual needles, Precision-GI™ utilizes a motorized mechanism designed to consistently deliver high-quality tissue core. This supports downstream clinical decisions and timely pancreatic cancer treatment for the patients.
EUS view of Precision-GI™ needle
High-quality core sample
Intact core adequate for histopathology evaluation
Our Story
Founded in 2017 as collaboration of The Trendlines Group, Rambam Health Care Campus, and the Israel Innovation Authority, Limaca Medical was built around a clear clinical need:
Improving the consistency and quality of tissue acquisition in endoscopic biopsy.
The company is dedicated to optimizing diagnostic pathways, which increasingly rely on molecular profiling and precision medicine in cancer care.
Through years of development and clinical validation, Limaca brought its next-generation technology from concept to the market.
Limaca Medical is now positioned to lead a new generation of motorized endoscopic biopsy, advancing endoscopic procedures toward more precise pancreatic cancer diagnosis.
Physician Feedback
Real-world perspectives from clinicians using Precision-GI™ in their daily practice.
“I am excited to partner with Limaca to help bring an amazing automated, 20-gauge EUS biopsy needle to the USA. We biopsied everything from lymph nodes to bile duct and pancreas masses successfully. Hackensack Meridian Health and Hackensack University Medical Center are leading the way to precise biopsy results with cutting-edge endoscopic capabilities.”
Dr. Rosario Ligresti
Chief of Gastroenterology, Hackensack University Medical Center Chief of Gastroenterology and Interventional Endoscopy, Hackensack Meridian Health
“The procedure with Precision GI is super easy for the physician, and the results after just one pass are phenomenal. The core sample is not fragmented or bloody. It’s very clear, it’s impressive. The quality of the biopsy tissue is amazing. Having used core needles for many years, I haven’t had samples that are not bloody, especially, for example, with the liver. This will be very revolutionary for quality of tissue overall.”
Dr. Carlos Robles-Medranda
Head of Endoscopy Service, Ecuadorian Institute of Digestive Diseases (IECED), Guayaquil, Ecuador Director, Pentax Training Center Ecuador (PTCE)
“The Limaca device was very simple and intuitive to use. This device standardizes the FNB process and takes out the variability among endoscopists to acquire adequate tissue samples.”
Dr. Mohamad Eloubeidi
Director of Endoscopy, Regional Medical Center (RMC) President, Alabama Gastroenterology Society
“I used the Limaca EUS-guided needle in a variety of pancreatic masses and one EUS-guided liver biopsy. The needle performed flawlessly. It passed through the endoscope easily, precise lesion puncture and very large core tissue specimens acquired.”
Dr. Isaac Raijman
Therapeutic Endoscopist & Gastroenterologist Clinical Associate Professor of Medicine, Baylor College of Medicine Texas International Endoscopy Center / TDDC Houston
Our Partners
Media and Press
Limaca Medical featured in CUTTING EDGE Magazine
Limaca Medical was featured in the latest Innovation Supplement of CUTTING EDGE magazine, a special project on Haaretz.com under “Haaretz Labels”.
Limaca Medical achieves its ISO 13485 Certification
This significant milestone further strengthens Limaca’s operational and quality infrastructure and joins the company’s FDA clearance, reinforcing our
U.S. Launch of Precision-GI™
Official commercial availability in the United States, supported by FDA clearance, Breakthrough designation and CMS TPT payment.